CompanyGraph
Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
603392 · SSE · China
ystwt.comFinancials as of FY2025
What stands out
- Revenue is growing, but receivables have grown faster over the last six to eight years
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $5.79B, above the global median of $1.18B
- FinancialsAltman Z-Score 12.81: safe zone
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Revenue is growing, but receivables have grown faster over the last six to eight years
Financials view
Market Capitalization
38.96BCNY5.79B · vs all stocks (USD)
Revenue (TTM)
1.94BCNY288.75M · vs all stocks (USD)
Profit Margin
-20.01%vs Biotechnology peers
Beta
0.7480xvs all stocks
52-Week Change
-47.85%vs all stocks
Market Capitalization
38.96BCNY5.79B · vs all stocks (USD)
Enterprise Value
31.63BCNY4.70B · vs all stocks (USD)
Forward P/E
54.05xvs Biotechnology peers
Price to Sales (TTM)
20.06xvs Biotechnology peers
Price to Book (MRQ)
3.28xvs Biotechnology peers
Enterprise to Revenue
16.29xvs Biotechnology peers
Enterprise to EBITDA
-77.08xvs Biotechnology peers
Gross Margin
69.86%vs Biotechnology peers
Profit Margin
-20.01%vs Biotechnology peers
Operating Margin
-10.89%vs Biotechnology peers
Return on Assets (TTM)
-3.10%vs Biotechnology peers
Return on Equity (TTM)
-3.32%vs Biotechnology peers
Revenue (TTM)
1.94BCNY288.75M · vs all stocks (USD)
Revenue per Share (TTM)
1.48CNYUpdated Aug 21, 2026Quarterly Revenue Growth
30.60%vs Biotechnology peers
Gross Profit (TTM)
790.77MCNY117.60M · vs all stocks (USD)
EBITDA (TTM)
-410.31MCNY-61.02M · vs all stocks (USD)
Net Income (TTM)
-388.47MCNY-57.77M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
30.63%vs Biotechnology peers
Operating Cash Flow (TTM)
-56.32MCNY-8.37M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
-537.49MCNY-79.93M · vs all stocks (USD)
Minority Interest (Equity)
168.46MCNYFY2025 · Dec 31, 2025Revenue
1.82BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
921.83MCNYFY2025 · Dec 31, 2025Gross Profit
897.14MCNYFY2025 · Dec 31, 2025Operating Income
-426.41MCNY-63.41M · vs all stocks (USD)
Pre-tax Income
-480.89MCNYFY2025 · Dec 31, 2025Income Tax Expense
-66.92MCNYFY2025 · Dec 31, 2025Net Income
-413.96MCNYFY2025 · Dec 31, 2025EBIT
-474.43MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
-8.30MCNYFY2025 · Dec 31, 2025Research & Development
560.80MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
211.22MCNYFY2025 · Dec 31, 2025Other Operating Expenses
21.48MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
32.90MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
6.46MCNYFY2025 · Dec 31, 2025EPS (Basic)
-0.3100CNYFY2025 · Dec 31, 2025EPS (Diluted)
-0.3100CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
1.28BSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
1.28BSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-413.96MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
15.70MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
-114.80MCNYFY2025 · Dec 31, 2025Free Cash Flow
-709.24MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.34BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-413.96MCNYFY2025 · Dec 31, 2025Other Non-cash Items
36.39MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
398.16MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-135.39MCNYFY2025 · Dec 31, 2025Capital Expenditures
-594.44MCNYFY2025 · Dec 31, 2025Purchase of Investments
-4.93BCNYFY2025 · Dec 31, 2025Sale of Investments
4.76BCNYFY2025 · Dec 31, 2025Other Investing Activity
2.79MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-759.01MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
343.56MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-319.01MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-2.28MCNYFY2025 · Dec 31, 2025Other Financing Charges
-21.80MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
471.66KCNYFY2025 · Dec 31, 2025Shares Outstanding
1.26BSharesUpdated Aug 21, 2026Float Shares
261.21MSharesUpdated Aug 21, 2026% Held by Insiders
81.93%vs all stocks
% Held by Institutions
2.89%vs all stocks
Total Cash (MRQ)
4.31BCNY640.75M · vs all stocks (USD)
Total Cash per Share (MRQ)
3.41CNYUpdated Aug 21, 2026Total Debt (MRQ)
355.03MCNY52.80M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0296xvs Biotechnology peers
Current Ratio (MRQ)
4.21xvs Biotechnology peers
Book Value per Share (MRQ)
9.38CNYUpdated Aug 21, 2026Total Assets
14.04BCNY2.09B · vs all stocks (USD)
Total Current Assets
7.53BCNYFY2025 · Dec 31, 2025Total Liabilities
2.01BCNYFY2025 · Dec 31, 2025Total Non-current Assets
6.52BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
208.75MCNYFY2025 · Dec 31, 2025Total Current Liabilities
1.80BCNYFY2025 · Dec 31, 2025Cash
2.42BCNYFY2025 · Dec 31, 2025Cash Equivalents
12.47MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
2.43BCNYFY2025 · Dec 31, 2025Other Short-term Investments
1.45BCNYFY2025 · Dec 31, 2025Accounts Receivable
1.62BCNYFY2025 · Dec 31, 2025Inventory
702.08MCNYFY2025 · Dec 31, 2025Accounts Payable
415.94MCNYFY2025 · Dec 31, 2025Short-term Debt
210.03MCNYFY2025 · Dec 31, 2025Other Current Liabilities
2.75MCNYFY2025 · Dec 31, 2025Long-term Debt
144.36MCNYFY2025 · Dec 31, 2025Common Stock (Book)
1.26BCNYFY2025 · Dec 31, 2025Retained Earnings
6.83BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
12.03BCNY1.79B · vs all stocks (USD)
52-Week Low
25.58CNYUpdated Aug 21, 202652-Week High
62.56CNYUpdated Aug 21, 202652-Week Change
-47.85%vs all stocks
Beta
0.7480xvs all stocks
50-Day MA
29.03CNYUpdated Aug 21, 2026200-Day MA
39.16CNYUpdated Aug 21, 2026Avg 10-Day Volume
6.76MSharesUpdated Aug 21, 2026Avg 30-Day Volume
6.14MSharesUpdated Aug 21, 2026Diluted EPS (TTM)
-0.3000CNYUpdated Aug 21, 20263 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Diagnostic
Inverse RSI (1Y) Elevated With Four-Year Net Income And Gross Profit Decreases
The price reads stretched low, and net income and gross profit have fallen four years.
Reads
Diagnostic
Declining With Price Stretched Below 1Y Mean
The price sits well below its yearly mean, with net income and assets falling four years.
Reads
Down-Close Share With Multi-Year Earnings Decrease
Most weeks closed down this year, and earnings and gross profit fell over four.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Revenue is growing, but receivables have grown faster over the last six to eight yearsSignificant
Revenue Growth YoY: 0.31Receivables vs revenue divergence: 4.89
High gross margins eroded by operating costsNotable
Gross Margin: 0.70Profit Margin: -0.20
Financial Health
Altman Z-Score 12.81: safe zoneNotable
Altman Z-Score: 12.81
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $5.79B, above the global median of $1.18BNotable
Market cap (USD): 5,793,138,178.095Global Median: 1,179,398,897.704
Companies that share the same coordination system — how they create, deliver, or capture value.
Xenon Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shenzhen Salubris Pharmaceuticals Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Crispr Therapeutics AG
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Junshi Biosciences Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Definium Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Ptc Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
APT Medical Inc.
Tier 1ProductionApproval-Gated PipelineRule
Mirum Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sectra AB
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Companies that share active interpretations — structural patterns currently present in both stocks.
Gc Cell Corp.
3 interpretationsDown-Close Share With Multi-Year Earnings DecreaseDeclining With Price Stretched Below 1Y MeanInverse RSI (1Y) Elevated With Four-Year Net Income And Gross Profit Decreases
Wintao Communications Co.
2 interpretationsDown-Close Share With Multi-Year Earnings DecreaseInverse RSI (1Y) Elevated With Four-Year Net Income And Gross Profit Decreases
Ibstock plc
2 interpretationsDown-Close Share With Multi-Year Earnings DecreaseDeclining With Price Stretched Below 1Y Mean